DigmBio
Developer of a novel dementia treatment designed to target the T1R3 GPCR. The company is engaged in drug development based on the novel target GPCR TASR platform by establishing an optimization progra...
Valuation
$0
Share Price
N/A
Total Raised
$10.6M
Last Round
N/A